Equities analysts forecast that Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) will post $11.59 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aquestive Therapeutics’ earnings, with estimates ranging from $10.08 million to $13.09 million. Aquestive Therapeutics reported sales of $15.35 million in the same quarter last year, which indicates a negative year-over-year growth rate of 24.5%. The firm is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Aquestive Therapeutics will report full year sales of $51.41 million for the current year, with estimates ranging from $47.05 million to $55.76 million. For the next fiscal year, analysts expect that the company will post sales of $72.88 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Aquestive Therapeutics.
Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. During the same quarter in the prior year, the company earned ($0.41) EPS.
NASDAQ AQST opened at $1.00 on Wednesday. Aquestive Therapeutics has a 12 month low of $0.97 and a 12 month high of $6.40. The company has a market capitalization of $41.91 million, a price-to-earnings ratio of -0.57 and a beta of 3.41. The company’s fifty day moving average price is $1.93 and its two-hundred day moving average price is $3.27.
Several hedge funds have recently added to or reduced their stakes in AQST. Morgan Stanley increased its holdings in shares of Aquestive Therapeutics by 54.7% in the 2nd quarter. Morgan Stanley now owns 553,727 shares of the company’s stock worth $2,198,000 after acquiring an additional 195,685 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Aquestive Therapeutics by 7.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 73,165 shares of the company’s stock worth $319,000 after acquiring an additional 5,135 shares during the period. Jump Financial LLC increased its holdings in shares of Aquestive Therapeutics by 62.3% in the 3rd quarter. Jump Financial LLC now owns 49,700 shares of the company’s stock worth $216,000 after acquiring an additional 19,070 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Aquestive Therapeutics by 203.9% in the 3rd quarter. GSA Capital Partners LLP now owns 297,229 shares of the company’s stock worth $1,296,000 after acquiring an additional 199,428 shares during the period. Finally, Balyasny Asset Management LLC acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $646,000. 38.98% of the stock is currently owned by institutional investors and hedge funds.
About Aquestive Therapeutics (Get Rating)
Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
- Get a free copy of the StockNews.com research report on Aquestive Therapeutics (AQST)
- 3 Defensive Consumer Stocks Worth Shopping For
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.